VKTX
Subcutaneous? Nice. Oral? Still on deck.
Viking Therapeutics is back in the chat with another VK2735 update, and the headline is pretty straightforward: the subcutaneous version of the drug is looking strong. If you’ve been following the obesity-drug race, you know that’s the kind of news that can make traders sit up like they just heard a snack bag rustle.
The catch — because there’s always a catch — is that the oral formulation data is still pending. So while the shot form seems to be checking the right boxes, investors don’t yet have the full picture on whether VK2735 can flex across both delivery methods.
Why the market cares
For Viking, this is less about one nice data point and more about keeping the story alive. Obesity drugs have become a brutal heavyweight contest, and every new readout matters because it helps answer the real question: is this a one-trick pony or a real contender?
Right now, the vibe is:
- Good news: subcutaneous results remain strong
- Missing piece: oral data still hasn’t shown up
- Investor takeaway: the bull case is intact, but not complete
Big picture: Viking is still in the game, but the finish line is nowhere near the finish line. In biotech, “promising” is nice — but “show me the next data set” is where the stock really gets judged.